Reflux and gastroparesis considerations Because GLP-1 medications slow gastric emptying, they can worsen symptoms in some people who already have reflux, severe indigestion, or suspected gastroparesis
This is the strongest argument for prioritizing muscle preservation throughout treatment
A patient with favorable GLP-1 receptor variants may experience stronger appetite suppression and lower rebound risk, while someone with FTO risk variants may need more structured behavioral support during and after treatment
The reduced weight loss in diabetic participants likely reflects insulin resistance and other metabolic factors that attenuate the response
Generally, for medications like Wegovy and Zepbound, which are approved for weight management, individuals must have a Body Mass Index (BMI) of 30 kg/m or greater (considered obese), or a BMI of 27 kg/m or greater (considered overweight) along with at least one weight-related comorbidity such as high blood pressure, type 2 diabetes, or high cholesterol
Soulera goes beyond conventional medicine by operating in the gap between "nothing is wrong" and "feeling your best." Every client receives a personalized protocol built around their biology, biomarkers, and goals, paired with ongoing clinical oversight and longevity-focused support
